Clinical Trials on Charles Bonnet Syndrome

Total 57681 results

M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Humanigen, Inc.

Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Myelodysplastic Syndrome (MDS) | Myelofibrosis (MF)

United States, Australia
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
Dongzhimen Hospital, Beijing

Not yet recruiting

Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation

MDS
Groupe Francophone des Myelodysplasies
Novartis; Neovii Biotech

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

MDS

France
Aprea Therapeutics

Completed

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

MDS

United States, France
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Rush University Medical Center
Celgene Corporation

Terminated

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

MDS

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
M.D. Anderson Cancer Center
S*BIO

Terminated

SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Bone Marrow Failure Syndromes | Severe Aplastic Anemia

United States
Ruijin Hospital

Recruiting

Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

Myelodysplastic Syndromes | Myelodysplastic Syndrome With Excess Blasts-2 | Myelodysplastic Syndrome With Excess Blasts-1

China
University Hospital, Tours
Novartis; Tours Autogreffe

Completed

Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls (PLASMYC)

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Ministry of Public Health, Democratic Republic...
National Institutes of Health (NIH); Oregon Health and Science University; National... and other collaborators

Completed

Cassava Intervention Project

Neurotoxicity Syndrome, Cassava | Neurotoxicity Syndrome, Cyanate | Neurotoxicity Syndrome, Cyanide | Neurotoxicity Syndrome, Thiocyanate

Congo, The Democratic Republic of the
University of British Columbia

Completed

Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders

Hematological Malignancy | Bone Marrow Failure Syndrome

Canada
National Cancer Institute (NCI)

Not yet recruiting

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes

United States
Vor Biopharma

Recruiting

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celgene

Completed

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, United Kingdom
Washington University School of Medicine

Completed

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Hadassah Medical Organization
Bayer

Withdrawn

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
Richard Stone, MD
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Active, not recruiting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
Cooperative Study Group A for Hematology

Completed

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (CyFluCyATG)

Bone Marrow Failure Syndromes

Korea, Republic of
Center for International Blood and Marrow Transplant...
Medical College of Wisconsin

Completed

Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

Myelodysplastic Syndromes | Hematopoietic Cell Transplant

United States
Washington University School of Medicine

Completed

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States, Australia, Canada
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Washington University School of Medicine
Notable Labs

Recruiting

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Seagen Inc.

Recruiting

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Netherlands
Institut Paoli-Calmettes

Recruiting

HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies (MICROSTEM)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Bellicum Pharmaceuticals

Terminated

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
The Cleveland Clinic
Celgene

Withdrawn

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Yale University

Withdrawn

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Fox Chase Cancer Center

Terminated

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
medac GmbH

Completed

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany, Italy, Poland, France, Finland, Hungary
Masonic Cancer Center, University of Minnesota

Completed

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States

Clinical Trials on Charles Bonnet Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations